Log in
Log in
E-mail
Password

Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Relief Therapeutics Holding AG
  6. Summary
    RLF   CH0100191136

RELIEF THERAPEUTICS HOLDING AG

(RLF)
  Report
Delayed Swiss Exchange  -  11:30 2022-06-24 am EDT
0.0293 CHF   +3.17%
06/21Acer Therapeutics Shares Hit 52-Week Low After FDA Rejects ACER-001
DJ
06/21Relief Therapeutics, Acer's New Drug Application For Urea Cycle Disorders Drug Rejected by US FDA; Shares Sink 9%
MT
06/21ACER THERAPEUTICS : FDA Rejects ACER-001 Application
DJ
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Swiss Exchange
06/20/2022 06/21/2022 06/22/2022 06/23/2022 06/24/2022 Date
0.0265(c) 0.0245(c) 0.0261(c) 0.0284(c) 0.0293(c) Last
5 184 505 15 459 570 9 831 244 17 634 158 7 445 142 Volume
-5.02% -7.55% +6.53% +8.81% +3.17% Change
More quotes
Estimated financial data (e)
Sales 2022 20,0 M 20,9 M 20,9 M
Net income 2022 - - -
Net Debt 2022 - - -
P/E ratio 2022 -
Yield 2022 -
Sales 2023 96,0 M 101 M 101 M
Net income 2023 - - -
Net Debt 2023 - - -
P/E ratio 2023 -
Yield 2023 -
Capitalization 121 M 126 M 126 M
Capi. / Sales 2022 6,03x
Capi. / Sales 2023 1,26x
Nbr of Employees 10
Free-Float 62,7%
More Financials
Company
RELIEF THERAPEUTICS Holding SA is a Switzerland-based biopharmaceutical company. The Company’s objective is to provide patients with therapeutic relief in serious diseases with high unmet medical need, as well as to focus on developing treatments for respiratory diseases. It specializes in clinical-stage projects based on molecules of natural origin (peptides and proteins with a history of clinical use and either... 
Read more
More about the company
All news about RELIEF THERAPEUTICS HOLDING AG
06/21Acer Therapeutics Shares Hit 52-Week Low After FDA Rejects ACER-001
DJ
06/21Relief Therapeutics, Acer's New Drug Application For Urea Cycle Disorders Drug Rejected..
MT
06/21ACER THERAPEUTICS : FDA Rejects ACER-001 Application
DJ
06/21Acer Therapeutics and Relief Therapeutics Announce Update on U.S. FDA Review of New Dru..
EQ
06/21Acer Therapeutics and Relief Therapeutics Announce Update on U.S. FDA Review of New Dru..
AQ
06/21Acer Therapeutics and Relief Therapeutics Announce Update on U.S. FDA Review of New Dru..
CI
06/17Relief Therapeutics Files Amendment No. 3 to its Registration Statement on Form 20-F wi..
EQ
06/13US FDA Rejects Relief Therapeutics Partner NRx's Breakthrough Request For Zyesami
MT
06/13Relief Reports that its U.S. Collaboration Partner has Announced an Update on Breakthro..
EQ
06/08Relief Therapeutics' Collaboration Partner Acer Therapeutics Awaits US FDA Nod On Urea ..
MT
06/08Relief Reports that its Collaboration Partner, Acer Therapeutics, Issued a Statement Re..
EQ
06/01Relief Therapeutics Announces Results of Annual General Meeting of RELIEF THERAPEUTICS ..
EQ
05/31Relief Therapeutics To Continue Developing Aviptadil For Other Indications After US Hal..
MT
05/31Relief Provides a Corporate Update and Comments on the Recently Announced DSMB Update o..
EQ
05/26Relief Therapeutics' Partners Receives Review For COVID-19 Drug Trial
MT
More news
News in other languages on RELIEF THERAPEUTICS HOLDING AG
06/21BOURSE ZURICH : les indices terminent en ordre dispersé
06/21RELIEF : la FDA réclame plus d'informations sur l'Acer-001
06/21La FDA américaine rejette la demande de nouveau médicament de Relief Therapeutics, Acer..
06/21Relief und Partner Acer erleiden Rücksetzer mit US-Zulassungsantrag
06/21Acer Therapeutics et Relief Therapeutics annoncent une mise à jour de l'examen par la F..
More news
Chart RELIEF THERAPEUTICS HOLDING AG
Duration : Period :
Relief Therapeutics Holding AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends RELIEF THERAPEUTICS HOLDING AG
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 0
Last Close Price 0,03 CHF
Average target price 0,41 CHF
Spread / Average Target 1 282%
Managers and Directors
Jack M. Weinstein Chief Financial Officer & Treasurer
Raghuram Selvaraju Chairman
Nermeen Varawalla Chief Medical Officer
Taneli Jouhikainen Chief Operating Officer
Thomas Plitz Director
Sector and Competitors
1st jan.Capi. (M$)
RELIEF THERAPEUTICS HOLDING AG-54.34%112
MODERNA, INC.-43.59%54 123
IQVIA HOLDINGS INC.-25.02%38 185
LONZA GROUP AG-35.92%38 059
SEAGEN INC.12.55%31 230
ALNYLAM PHARMACEUTICALS, INC.-13.73%17 102